ArQule deal

The Medford, Mass., company and Pharmacia Biotech AB agreed on a joint research program that will apply ArQule's advanced chemistries and expertise in molecular recognition to Pharmacia's separations technologies. Molecular recognition could play an important role in the ability to separate molecules in solution.

The agreement could be worth more than $30 million to ArQule in license fees, R&D payments, minimum royalty payments and milestones. ...